AlphAIAlphAI — Financial news for AI agents
investing.comOCT 202 min read$RAPP

Truist reiterates Rapport Therapeutics stock rating on trial data

Truist Securities reiterated a Buy rating and $56.00 price target for Rapport Therapeutics (RAPP) after positive clinical trial results for RAP-219 in bipolar mania. The stock is currently trading at $29.74, with a Wall Street consensus of Strong Buy and price targets ranging from $50 to $80. Analysts noted consistent efficacy, a clean safety profile, and planned Phase 3 enhancements. The company maintains a strong financial position with a current ratio of 15.72.

Original reporting
investing.com
Published Oct 20, 2026, 3:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 3:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$RAPP
Bullish
high confidence
Mentioned
$RAPP
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RAPPBullishHigh
01

Why it matters

The trial data triggered multiple analyst upgrades and higher price targets, indicating a fresh catalyst for the stock.

02

Market read

Positive trial data and analyst upgrades create a short‑term bullish catalyst for RAPP.

03

What to watch

Potential regulatory hurdles and competition from other bipolar mania treatments may temper long‑term upside.

Relevance 8/10Novelty 8/10Timing: today

Background

The article summarizes analyst reactions to a Phase II trial readout for Rapport Therapeutics' candidate RAP-219.

Company-level read

Ticker impact

$RAPPBullishHigh confidence
Context

Truist reiterated a Buy rating and raised the price target to $56 after reporting positive Phase II trial results for RAP-219 in bipolar mania.

Expected impact

upward pressure as the market prices in the positive trial data and higher target.

Evidence & confidence

Multiple analysts upgraded RAPP and set higher targets following the same trial data, indicating consensus optimism.

Market effects

Sector

Positive biotech trial data may lift sentiment across psychiatric‑focused biotech peers.

Regional

U.S. biotech sector could see modest gains in pre‑market trading.

Global

Limited to investors tracking U.S. biotech and mental‑health drug pipelines.

Counterpoint

What could challenge this read

If the Phase II data fails to translate into Phase III success, the current upside could be overstated.

Key entities

  • analyst
    Truist Securities

    Reiterated Buy rating and $56 price target.

  • company
    Rapport Therapeutics

    Biotech firm reporting Phase II trial results for RAP-219.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 21
$RAPPMed

Jones Trading raises Rapport Therapeutics price target on pipeline potential

Jones Trading raised its price target for Rapport Therapeutics (RAPP) to $82 from $50, maintaining a Buy rating. The firm cited positive clinical trial results for the company’s RAP-219 drug candidate in FOS and BPM indications. The stock currently trades at $29.37, giving the company a market capitalization of $1.41 billion. Analysts have varied price targets and ratings for RAPP, with a consensus Strong Buy rating.

investing.com1 min
OCT 20
$RAPPHigh

RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study

RAPP stock initially rose but later tempered gains due to concerns over higher discontinuation rates in a bipolar mania study. Analysts at H.C. Wainwright and Raymond James raised their price targets to $66 and $86 respectively, while Wells Fargo maintained an Overweight rating with a $51 target. Retail traders on Stocktwits reacted bullishly, with some suggesting the company is a potential buyout candidate. The stock is down 3% year-to-date.

finance.yahoo.com2 min
OCT 20
$RAPPMedAI 8/10

Guggenheim raises Rapport Therapeutics price target to $70 on trial data

Guggenheim raised its price target on Rapport Therapeutics (RAPP) to $70 from $65, citing positive Phase 2 trial results for bipolar mania. The trial met primary and secondary endpoints, with a 3.1-point placebo-adjusted YMRS reduction. Guggenheim increased its success probability to 65% and adjusted its expected launch to 2030. The stock is currently trading at $30.20, with a Strong Buy consensus among analysts.

investing.com1 min
OCT 20
$RAPPHighAI 8/10

TD Cowen reiterates Buy on Rapport Therapeutics stock after trial

TD Cowen reiterated a Buy rating on Rapport Therapeutics (RAPP) after positive Phase II trial results for RAP-219 in bipolar mania. The trial met primary and secondary endpoints, with a 3.1 point placebo-adjusted improvement on the Young Mania Rating Scale. TD Cowen estimates peak sales of $2.9 billion for RAP-219 and values RAPP at $60 per share, citing strong financial health and pipeline potential.

investing.com2 min
OCT 20
$RAPPMedAI 8/10

BTIG raises Rapport Therapeutics price target to $89 on trial data

BTIG raised its price target for Rapport Therapeutics (NASDAQ:RAPP) to $89 from $75, citing positive clinical trial results for RAP-219 in mania. The stock is currently trading at $30.86. Analysts highlight the drug's efficacy and safety, with Wall Street maintaining a strong buy consensus. Other analysts have also raised price targets, reflecting optimism about RAP-219's potential in treating bipolar mania and epilepsy.

investing.com2 min